Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Amortization of Deferred Charges (2019 - 2025)

Benitec Biopharma's Amortization of Deferred Charges history spans 7 years, with the latest figure at $93000.0 for Q1 2025.

  • For Q1 2025, Amortization of Deferred Charges rose 43.08% year-over-year to $93000.0; the TTM value through Mar 2025 reached $291000.0, up 14.57%, while the annual FY2024 figure was $256000.0, 4.49% up from the prior year.
  • Amortization of Deferred Charges for Q1 2025 was $93000.0 at Benitec Biopharma, up from $67000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $93000.0 in Q1 2025 and bottomed at $48000.0 in Q1 2021.
  • The 5-year median for Amortization of Deferred Charges is $61000.0 (2022), against an average of $61764.7.
  • The largest annual shift saw Amortization of Deferred Charges increased 1.67% in 2023 before it soared 43.08% in 2025.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $58000.0 in 2021, then increased by 5.17% to $61000.0 in 2022, then grew by 3.28% to $63000.0 in 2023, then grew by 6.35% to $67000.0 in 2024, then skyrocketed by 38.81% to $93000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Amortization of Deferred Charges are $93000.0 (Q1 2025), $67000.0 (Q4 2024), and $66000.0 (Q3 2024).